Abstract
PD-1/PD-L1-checkpoint blockade therapy is generally thought to relieve tumor cell-mediated suppression in the tumor microenvironment but PD-L1 is also expressed on non-tumor macrophages and conventional dendritic cells (cDCs). Here we show in mouse tumor models that tumor-draining lymph nodes (TDLNs) are enriched for tumor-specific PD-1+ T cells which closely associate with PD-L1+ cDCs. TDLN-targeted PD-L1-blockade induces enhanced anti-tumor T cell immunity by seeding the tumor site with progenitor-exhausted T cells, resulting in improved tumor control. Moreover, we show that abundant PD-1/PD-L1-interactions in TDLNs of nonmetastatic melanoma patients, but not those in corresponding tumors, associate with early distant disease recurrence. These findings point at a critical role for PD-L1 expression in TDLNs in governing systemic anti-tumor immunity, identifying high-risk patient groups amendable to adjuvant PD-1/PD-L1-blockade therapy.
Original language | English |
---|---|
Pages (from-to) | 685-700.e8 |
Journal | Cancer Cell |
Volume | 38 |
Issue number | 5 |
Early online date | 1 Oct 2020 |
DOIs | |
Publication status | Published - 9 Nov 2020 |
Bibliographical note
Copyright © 2020 Elsevier Inc. All rights reserved.Research programs
- EMC MGC-02-13-02
- EMC MM-02-72-02
- EMC MM-03-24-01
- EMC MM-04-42-02